A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Inclusion Criteria: * Healthy Male or female between 18 and 55 years of age * A female subject is eligible to participate if she is of non-childbearing potential * Male subjects must agree to use one of the contraception methods listed in the protocol * BMI within the range 20 - 29.9 kg/m2 * Capable of giving written informed consent, which includes compliance with protocol * QTcB or QTcF \< 450msec. Exclusion Criteria: * The subject has a positive pre-study drug/alcohol screen * Positive urinary cotinine levels or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. * History of regular alcohol consumption within 6 months of the study * History of sensitivity to heparin or heparin-induced thrombocytopenia * Unable or unwilling to abstain from caffeine-or xanthine-containing products for 24 hours prior to dosing until the final post-dose assessment at each treatment level. * Use of illicit drugs. * Use of alcohol for 24 hours prior to dosing until final post-dose assessment at each treatment level. * Consumption of red wine, oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until collection of the final pharmacokinetic and pharmacodynamic blood samples * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening * A positive test for HIV antibody * Pregnant females as determined by positive urine hCG test at screening or…